AUPH Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Aurinia Pharmaceuticals Inc. had $283M of revenue in fiscal 2025, up 20.4% on the year before. Over five years, revenue changed +41.4% a year on average.
Last close Β· Oct 23, 2026
$16.86
2.7%Hi! I read Aurinia Pharmaceuticals Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+20.4%
Yes. Sales grew 20.4% last year.
Does it make a profit?
101.5%
Yes. It keeps 101.5% of every sale as profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
7.4x
One share costs 7.4 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Aurinia Pharmaceuticals Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 7, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Feb 26, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 4, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 31, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 12, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Feb 27, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Aurinia Pharmaceuticals Inc. had $283M of revenue in fiscal 2025, up 20.4% on the year before. Over five years, revenue changed +41.4% a year on average. Its operating margin was 37.1%, up 39.1Β pts: of every 100 in sales, about 37 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Aurinia Pharmaceuticals Inc. made $287M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Aurinia Pharmaceuticals Inc. returned $98.2M to shareholders in fiscal 2025. The diluted share count fell 5.1%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Aurinia Pharmaceuticals Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Interest coverage | β | β | β33.0x | β1.0x | 24.2x |
| Current ratio | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Quick ratio | 12.2x | 9.1x | 5.0x | 4.2x | 4.8x |
| Total assets | $543M | $471M | $548M | $551M | $752M |
| Total liabilities | $64.3M | $65.4M | $170M | $173M | $170M |
| Shareholders' equity | $479M | $405M | $378M | $377M | $581M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Aurinia Pharmaceuticals Inc. passes 6 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 3 / 8 | 1 / 8 | 3 / 8 | 3 / 8 | 5 / 8 | 6 / 8 |
| Accruals ratio | β | β7.6% | β8.3% | β4.6% | β5.6% | β8.7% | β7.0% | 23.3% |
| Altman Z'' | β | 11.71 | 7.58 | 6.76 | 4.46 | β0.24 | 0.84 | 5.18 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0.5M | $0.3M | $50.1M | $45.6M | $134M | $176M | $235M | $283M |
| Gross profit | β | $0.3M | $50.1M | $44.5M | $128M | $161M | $207M | $250M |
| Research and development | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M |
| Operating income | β$55.2M | β$90.9M | β$104M | β$181M | β$111M | β$91.7M | β$4.7M | $105M |
| Interest expense | β | β | β | $0.0M | $0.0M | $2.8M | $4.8M | $4.3M |
| Pretax income | β$53.0M | β$88.2M | β$103M | β$180M | β$106M | β$77.5M | $7.4M | $114M |
| Income tax | $0.1M | $0.1M | β$0.1M | $0.8M | $1.8M | $0.6M | $1.7M | β$173M |
| Net income | β$53.1M | β$88.4M | β$103M | β$181M | β$108M | β$78.0M | $5.8M | $287M |
| Diluted EPS | β$0.63 | β$0.95 | β$0.87 | β$1.40 | β$0.76 | β$0.54 | $0.04 | $2.07 |
| Diluted shares | 0.08B | 0.09B | 0.12B | 0.13B | 0.14B | 0.14B | 0.15B | 0.14B |
| Cash flow | ||||||||
| Cash from operations | β$51.6M | β$63.6M | β$69.9M | β$158M | β$79.5M | β$33.5M | $44.4M | $136M |
| Depreciation and amortization | $0.0M | $0.0M | $1.4M | $2.8M | $2.7M | $11.6M | $19.4M | $19.4M |
| Stock-based compensation | $6.9M | $7.4M | $17.5M | $31.2M | $32.3M | $45.3M | $31.6M | $14.7M |
| Share buybacks | β | β | β | β | $0.0M | $0.0M | $40.2M | $98.2M |
| Dividends and buybacks | β | β | β | β | $0.0M | $0.0M | $40.2M | $98.2M |
| Balance sheet | ||||||||
| Cash and short-term investments | $118M | $306M | $272M | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Finance lease liabilities | β | β | β | β | β | $90.1M | $72.6M | $68.8M |
| Current assets | β | $315M | $419M | $513M | $443M | $425M | $447M | $492M |
| Current liabilities | β | $11.3M | $32.0M | $40.6M | $46.1M | $77.2M | $97.8M | $93.7M |
| Inventory | β | $0.0M | $13.9M | $19.3M | $24.8M | $39.7M | $39.2M | $45.7M |
| Property and equipment, net | β | $0.1M | $4.8M | $4.4M | $3.7M | $3.4M | $2.7M | $2.1M |
| Intangible assets | β | $8.9M | $9.3M | $8.4M | $6.4M | $5.0M | $4.4M | $3.8M |
| Total assets | β | $324M | $464M | $543M | $471M | $548M | $551M | $752M |
| Total liabilities | β | $25.7M | $55.9M | $64.3M | $65.4M | $170M | $173M | $170M |
| Shareholders' equity | $136M | $299M | $408M | $479M | $405M | $378M | $377M | $581M |
| Margins | ||||||||
| Gross margin | β | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | β11,930.9% | β28,598.4% | β208.1% | β396.3% | β83.2% | β52.2% | β2.0% | 37.1% |
| EBITDA margin | β11,926.6% | β28,588.1% | β205.4% | β390.3% | β81.1% | β45.6% | 6.3% | 43.9% |
| Net margin | β11,464.1% | β27,794.0% | β204.9% | β396.8% | β80.7% | β44.5% | 2.4% | 101.5% |
| Returns | ||||||||
| Return on capital employed | β | β29.1% | β24.2% | β36.0% | β26.2% | β19.5% | β1.0% | 15.9% |
| Return on equity | β39.1% | β40.7% | β29.1% | β40.8% | β24.5% | β19.9% | 1.5% | 59.9% |
| Return on assets | β | β27.3% | β26.1% | β35.9% | β21.3% | β15.3% | 1.0% | 44.1% |
| Return on tangible equity | β39.1% | β30.5% | β25.8% | β38.4% | β27.1% | β20.9% | 1.5% | 49.7% |
| Growth | ||||||||
| Revenue growth | β | β31.3% | 15,660.4% | β9.0% | 193.9% | 31.0% | 34.0% | 20.4% |
| Net income growth | β | β | β | β | β | β | β | 4,893.1% |
| EPS growth | β | β | β | β | β | β | β | 5,075.0% |
| Share count change | β | 9.7% | 27.4% | 9.2% | 9.7% | 0.9% | 2.1% | β5.1% |
| Financial health | ||||||||
| Interest coverage | β | β | β | β | β | β33.0x | β1.0x | 24.2x |
| Current ratio | β | 27.9x | 13.1x | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Quick ratio | β | 27.9x | 12.7x | 12.2x | 9.1x | 5.0x | 4.2x | 4.8x |
| Capital allocation | ||||||||
| Stock comp / revenue | 1,481.6% | 2,331.4% | 34.8% | 68.5% | 24.1% | 25.8% | 13.4% | 5.2% |
| Quality scores | ||||||||
| Piotroski F-score | β | β | 3.0 | 1.0 | 3.0 | 3.0 | 5.0 | 6.0 |
| Altman Z'' | β | 11.7 | 7.6 | 6.8 | 4.5 | β0.2 | 0.8 | 5.2 |
| Accruals ratio | β | β7.6% | β8.3% | β4.6% | β5.6% | β8.7% | β7.0% | 23.3% |
Source: SEC EDGAR XBRL filings (CIK 0001600620). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
